NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy takes aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study tracks safety of ultomiris in pregnant women
Knowledge-focused Recruiting nowThis study follows 75 pregnant women who have taken Ultomiris (ravulizumab) for conditions like PNH or aHUS. Researchers will track pregnancy outcomes and baby health up to one year after birth. The goal is to gather safety information, not to test a new treatment.
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC